Heat Biologics to Provide Corporate Update
Heat Biologics, (NASDAQ: HTBX), a clinical-stage biopharmaceutical company, announced a conference call on September 2nd at 11:00 AM ET, hosted by CEO Jeff Wolf. The call aims to provide updates on the company's activities and can be accessed via phone or webcast. Heat Biologics is focused on developing therapies to modulate the immune system, utilizing its gp96 platform. The company has multiple products in development, including HS-110, which has completed enrollment in a Phase 2 trial, and several programs in preclinical and early clinical stages.
- HS-110 has completed enrollment in a Phase 2 trial, indicating progress in clinical development.
- Multiple product candidates are in development leveraging the gp96 platform, showcasing a diverse pipeline.
- None.
Conference call scheduled for September 2nd at 11:00 AM ET
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company’s activities.
The conference call may be accessed by dialing 844-602-0380 for U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2768/42602 or on the Company’s website at https://ir.heatbio.com/.
An audio replay of the call will be available through September 16, 2021, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 42602.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: www.heatbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com
FAQ
What is the date and time for the Heat Biologics conference call?
How can I access the September 2nd conference call for Heat Biologics?
What are the main products in development at Heat Biologics?
What stage is HS-110 in its clinical trial process?
